Rob Fried is Chief Executive Officer of Niagen Bioscience, the global leader in NAD+ science and commercialization. With over a decade of experience in the bioscience and longevity space, he has led the company since 2018, following roles as President and COO and an earlier appointment to the Board of Directors in 2015.
In 2016, Rob founded Healthspan Research, which developed the consumer-facing Tru Niagen® brand prior to its acquisition by ChromaDex in 2017. His passion for advancing healthy aging is rooted in early investments across biotech, stem cell research, and regenerative medicine. He holds a B.S. from Cornell and an M.B.A. from Columbia Business School.